PLUS1
7.825
0.795 (11.31%)
0.795 (11.31%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaxart Inc | VXRT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.795 | 11.31% | 7.825 | 12:31:13 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.34 | 7.31 | 8.17 | 7.03 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 7.82 | 7.83 | 0.01 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 57,333 | 16,562,925 | $ 7.76 | $ 128,476,319 | 11,311,150 | 0.2805 - 17.49 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:31:14 | 50 | $ 7.8267 | USD |
Vaxart Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 847.90M | 109.47M | 83.54M | $ 9.86M | $ - | -0.79 | -58.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Vaxart News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/19/2020 | 11:35 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/12/2020 | 16:15 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/12/2020 | 16:03 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 10/14/2020 | 06:05 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 10/13/2020 | 17:29 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 10/08/2020 | 15:41 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 10/07/2020 | 08:02 | PR Newswire (US) | Centaur Biopharmaceutical Services Announces Expansion of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VXRT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.61 | 8.17 | 6.01 | 6.72 | 10,521,736 | 1.22 | 18.38% |
| 1 Month | 5.02 | 8.17 | 3.50 | 5.26 | 13,420,690 | 2.81 | 55.88% |
| 3 Months | 5.545 | 9.43 | 3.50 | 6.75 | 18,450,463 | 2.28 | 41.12% |
| 6 Months | 2.6931 | 17.49 | 2.10 | 8.61 | 21,860,684 | 5.13 | 190.56% |
| 1 Year | 0.3545 | 17.49 | 0.2805 | 6.79 | 15,228,134 | 7.47 | 2,107.33% |
| 3 Years | 7.469 | 17.49 | 0.2543 | 6.60 | 5,488,708 | 0.356 | 4.77% |
| 5 Years | 20.35 | 25.08 | 0.2543 | 6.65 | 3,352,947 | -12.53 | -61.55% |
Vaxart Description
| Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. |
